

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following descriptions best characterizes the incidence of Grade ≥ 3 immune-related adverse events (AEs) in the Phase III ATOMIC study evaluating the addition of atezolizumab to standard chemotherapy for resected mismatch repair-deficient (dMMR) /microsatellite instability-high (MSI-H) Stage III colon cancer?**
 - a. The addition of atezolizumab resulted in significantly more Grade ≥ 3 immune-related AEs overall
 - b. The addition of atezolizumab resulted in significantly more Grade ≥ 3 endocrinopathies but not other immune-related AEs
 - c. No clinically significant differences in Grade ≥ 3 immune-related AEs were reported**
- 2. A Phase II study of dostarlimab for 49 patients with previously untreated, unresected locally advanced dMMR/MSI-H rectal cancer reported which of the following efficacy outcomes?**
 - a. No clinical complete responses (CCRs)
 - b. 33% cCR rate
 - c. 66% cCR rate
 - d. 100% cCR rate**
- 3. The efficacy and safety findings from the Phase II DESTINY-CRC02 trial supported which dose level of trastuzumab deruxtecan for patients with HER2-positive colorectal cancer (CRC)?**
 - a. The results supported the use of either 5.4 mg/kg or 6.4 mg/kg
 - b. 5.4 mg/kg**
 - c. 6.4 mg/kg
- 4. Which of the following outcomes best represents results of the Phase III CALGB/SWOG-80702 trial evaluating the addition of celecoxib versus placebo to standard adjuvant therapy for patients with Stage III colon cancer?**
 - a. No significant overall survival (OS) improvement among patients with and without detectable ctDNA
 - b. Significant OS improvement among patients with detectable ctDNA**
 - c. Significant OS improvement among patients with and without detectable ctDNA
- 5. The Phase III STELLAR-303 study is investigating the efficacy and safety of which of the following agents in combination with atezolizumab for patients with metastatic CRC?**
 - a. Tucatinib
 - b. Zanzalitinib**
 - c. Encorafenib
 - d. Sotorasib